IBTK and B-cell chronic lymphocytic leukemia: In these two trials, the treatment combination of BTKi (ibrutinib) and BCL2i (venetoclax) resulted in a high uMRD rate (36% in r/r CLL patients [115] and 61% in untreated high-risk and older patients with CLL [114]).